Clinical trial
Prospective, open-label, non-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of octagam 10% in primary immune thrombocytopenia
To assess the efficacy of Octagam 10% in correcting the platelet count (PC).
| Category | Value |
|---|---|
| Study start date | 2012-04-04 |